ABOUT

Introduction and Company Milestones

Company Establishment and Growth

Bestat Pharmaservices Corp. was founded in 2013 in Taipei, Taiwan, laying a strong foundation for providing comprehensive clinical trial services. In the ensuing years, the company experienced steady growth and garnered significant recognition. Bestat was honored with the 17th Golden Peak Award in 2016, being named among Taiwan’s Top 10 Outstanding Enterprises, and its founder, Samuel Su, received a Top 10 Outstanding Entrepreneurs Award that same year. In 2018, the company earned Taipei City’s Outstanding Investment Enterprise Award, reflecting its positive impact and growth. To accommodate its expanding operations, Bestat relocated its headquarters to Taipei’s Songshan District in 2022. By 2025, it further broadened its capabilities through the strategic acquisition of TRINEO BIOTECHNOLOGY CO., LTD., integrating preclinical pharmacology and toxicology services into its portfolio.

Clinical Milestones

In its clinical research endeavors, Bestat achieved numerous pioneering milestones. By 2014, the company had spearheaded several first-of-its-kind trials in Taiwan, including the first Phase II trial of a botanical new drug, the first Phase III trial in breast cancer, the first medical device registration trial, and its first dedicated drug safety monitoring project. In 2015, Bestat went on to complete Taiwan’s first Phase I clinical trial in the field of cell therapy. By 2018, it had also concluded more than ten clinical trials for medical devices, reflecting an expanding and diverse research portfolio. In 2020, Bestat further advanced its capabilities by conducting its first multi-regional Phase III trial and by launching its first overseas study – a Phase II COVID-19 vaccine trial in the United States. This momentum continued into 2024, when the company completed its first U.S.-based Phase III clinical trial. By the end of 2024, Bestat’s clinical experience spanned over 20 therapeutic areas (including oncology, infectious diseases, metabolic disorders, dermatology and more), with oncology studies alone exceeding 80 projects, and the company had enrolled over 1,500 trial participants across drug, biologic, cell therapy, and medical device trials.

Global Expansion and Partnerships

Bestat steadily expanded its presence beyond Taiwan through strategic international initiatives. In 2017, the company submitted its first Investigational New Drug (IND) application to the U.S. FDA, marking the beginning of its engagement with U.S. regulators. By 2019, Bestat was also working closely with authorities in Asia, holding its first consultation with China’s National Medical Products Administration (NMPA) for a Phase III trial. In 2020, the company conducted its first overseas clinical trial — a Phase II COVID-19 vaccine study in the United States — and became a strategic partner of U.S.-based Medidata, strengthening its global technological capabilities. In 2025, Bestat signed partnership agreements with multiple contract research organizations in Australia, extending its service portfolio to include Phase I trials in that region. Through these expansions and alliances, the company established a robust international network and broadened its global footprint.

Regulatory and Compliance Progress

Throughout its growth, Bestat prioritized regulatory compliance and high quality standards. This focus was exemplified in 2016 when the company completed its first Phase III trial that successfully passed a Good Clinical Practice (GCP) inspection in Taiwan, demonstrating adherence to international clinical guidelines. In 2017, Bestat obtained a Medical Device Business Permit to support work on medical device trials. That same year, it was recognized as a recommended CRO by Taiwan’s Center for Drug Evaluation (CDE) and approved by the Ministry of Economic Affairs as an authorized pharmaceutical R&D service provider. Bestat further proved its compliance capabilities abroad in 2021 by passing a GCP inspection by Chinese authorities for a Phase III botanical drug trial. To bolster its regulatory services, the company established comprehensive pharmacovigilance solutions in 2022 and obtained a Wholesale Drug Distribution License, enabling broader clinical and regulatory offerings. In 2023, Bestat further strengthened its compliance infrastructure by creating a dedicated Regulatory & Safety Division. By 2024, the company had successfully completed more than ten GCP-audited clinical trials, reflecting a robust track record in meeting global regulatory standards.

Technology and Innovation

Bestat continually embraced innovation to enhance its services. In 2014, the company secured Small Business Innovation Research (SBIR) and other R&D grants from the Taipei City Government, supporting its early development of novel solutions. In 2019, it implemented global CDISC data standards to improve clinical data management and interoperability. In 2023, Bestat became the first CRO in Taiwan to integrate a GPT-based artificial intelligence technology into its operations, underscoring its commitment to technological leadership.

Talent Development and Sustainability Strategy

Bestat has made significant strides in both talent development and sustainable business practices. In 2020, it expanded its medical team by recruiting full-time physicians and pharmacists, strengthening in-house expertise. In 2023, the company signed a Memorandum of Understanding with the Ministry of Labor to advance biotech talent development. By 2024, it had provided hands-on training to over 30 university and graduate-level interns, reflecting a commitment to nurturing the next generation of biotech professionals. Also in 2024, Bestat implemented a comprehensive ESG (Environmental, Social, and Governance) strategy by establishing a Sustainability Committee to lead carbon reduction initiatives, internal ESG data tracking, and collaborative projects with government, academic, and non-profit partners.

Mission

In view of the booming development of the biotechnology and pharmaceutical industry at home and abroad, it is often limited by insufficient talents and slow R & D schedules, leading to development difficulties at each stage. Bestat feels this, combining top domestic and foreign professional talents, teamwork, upholding the expertise of their respective fields, providing more efficient methods to achieve the highest quality, hoping to provide the best solution, and become the best partner of sponsors, together to make the greatest efforts for the pharmaceutical industry.

History

    2013
  • 1
    Bestat Pharmaservices Corp. was established in Taipei, Taiwan.
    2014
  • 1
    Completed the company's first Phase II clinical trial for a botanical new drug.
  • 2
    Conducted the first Phase III breast cancer clinical study.
  • 3
    Delivered the first medical device registration trial.
  • 4
    Initiated the first drug safety monitoring project.
  • 5
    Received Taipei City SBIR and R&D Incentive Program awards.
    2015
  • 1
    Successfully completed the first Phase I clinical trial in cell therapy.
    2016
  • 1
    Awarded the 17th Golden Peak Award – Top 10 Outstanding Enterprises.
  • 2
    Founder Samuel Su received the Top 10 Outstanding Entrepreneur Award.
  • 3
    Completed the first Phase III study to pass Taiwan GCP inspection.
    2017
  • 1
    Obtained the Medical Device Business Permit, enhancing regulatory services.
  • 2
    Submitted the first IND application to the US FDA.
  • 3
    Recognized by CDE as a recommended CRO in Taiwan.
  • 4
    Listed by MOEA as an approved pharmaceutical R&D service provider.
    2018
  • 1
    Received Taipei City's "Outstanding Investment Enterprise Award".
  • 2
    Completed more than 10 medical device clinical trials.
    2019
  • 1
    Implemented CDISC global data standards.
  • 2
    Completed the first NMPA/CDE Phase III consultation in China.
    2020
  • 1
    Conducted the first MRCT Phase III study.
  • 2
    Executed the first US-based Phase II COVID-19 vaccine trial.
  • 3
    Formed a strategic partnership with US-based MediData.
  • 4
    Expanded internal medical capabilities with full-time physicians and pharmacists.
    2021
  • 1
    Completed the first GCP inspection for a botanical Phase III study in China.
    2022
  • 1
    Established a comprehensive pharmacovigilance (PV) service platform.
  • 2
    Relocated headquarters to Songshan District, Taipei.
  • 3
    Obtained a Wholesale Drug Distributor License.
    2023
  • 1
    Signed an MOU with the Ministry of Labor to advance biotech talent development.
  • 2
    Launched the Regulatory & Safety Department.
  • 3
    Became the first CRO in Taiwan to adopt GPT-based AI technology.
    2024
  • 1
    Implemented an ESG strategy and established the Bestat Sustainability Committee to drive carbon reduction, ESG governance, and cross-sector collaboration.
  • 2
    Trained 30+ university and graduate-level interns.
  • 3
    Completed the first US-based Phase III clinical trial.
  • 4
    Expanded therapeutic experience across 20+ disease areas, with oncology studies surpassing 80 projects.
  • 5
    Delivered over 1,500 full-service clinical trial subjects.
  • 6
    Completed more than 10 GCP-inspected trials.
    2025
  • 1
    Formed strategic partnerships with CROs in Australia, expanding services to Phase I trials in Australia.
  • 2
    Acquired TRINEO BIOTECHNOLOGY CO., LTD., extending capabilities into preclinical pharmacology and toxicology.
Introduction
Mission
History
TOP